Aimmune Therapeutics, Inc. short interest in 2020
In 2020, Aimmune Therapeutics, Inc.'s disclosed short interest ran from 18.27% of shares outstanding on 15 Jan 2020 to 27.28% on 31 Aug 2020, a change of +9.01 percentage points. The year's high was 29.06% on 30 Jun 2020 and its low 18.27% on 15 Jan 2020, averaging 25.33% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.29 days on 29 May 2020. Full history: Aimmune Therapeutics, Inc..
Cite this page
2020 in figures
- Start of year
- 18.27% (15 Jan 2020)
- End of year
- 27.28% (31 Aug 2020)
- Change
- +9.01 pp
- High
- 29.06% (30 Jun 2020)
- Low
- 18.27% (15 Jan 2020)
- Average
- 25.33%
- Highest days to cover
- 24.29 (29 May 2020)
- SEC filings marked
- 6
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 18.27% | 10.39 | |
| 31 Jan 2020 | 18.94% | 12.47 | |
| 14 Feb 2020 | 22.45% | 4.68 | |
| 28 Feb 2020 | 23.30% | 9.84 | 10-K filed, results (8-K) |
| 13 Mar 2020 | 21.85% | 10.97 | |
| 31 Mar 2020 | 23.79% | 6.96 | |
| 15 Apr 2020 | 25.44% | 14.13 | |
| 30 Apr 2020 | 27.01% | 16.71 | |
| 15 May 2020 | 27.90% | 16.83 | 10-Q filed, results (8-K) |
| 29 May 2020 | 27.46% | 24.29 | |
| 15 Jun 2020 | 27.64% | 17.88 | |
| 30 Jun 2020 | 29.06% | 13.18 | |
| 15 Jul 2020 | 28.06% | 19.42 | |
| 31 Jul 2020 | 28.68% | 22.82 | 10-Q filed, results (8-K) |
| 14 Aug 2020 | 28.14% | 21.05 | |
| 31 Aug 2020 | 27.28% | 19.98 |
See also: Aimmune Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.